Furthermore, glucose starvation—as found in the ischemic regions of the tumor—maintains Cyr61 levels that are still suitable for the application of Cyr61 as a marker protein, with the exception of phenotypes like BC-M1 and LC-M1. This evidence concerns the gene CCN1 and breast cancer.